NCT01300468已完成1 期
A Phase I Study of Oral PHA-848125AC Given Daily For 7 Consecutive Days Every 2 Weeks or for 4 Consecutive Days A Week for 3 Consecutive Weeks Every 4 Weeks to Adult Patients With Advanced/Metastatic Solid Tumors
Nerviano Medical Sciences2 个研究点 分布在 1 个国家目标入组 38 人开始时间: 2006年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 38
- 试验地点
- 2
- 主要终点
- Determination of Dose Limiting Toxicities and Maximum Tolerated Dose
研究概览
简要总结
The purpose of this open-label, multi center, Phase I study was to determine the safety profile of the oral compound PHA-848125AC administered according to two different schedules of administrations to advanced/metastatic solid tumor patients. Objectives of the study were to determine the maximum tolerated dose and the dose that can be recommended for Phase II investigations.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed, written IRB-approved Informed Consent
- •Histologically or cytologically confirmed relapsed or refractory solid tumors for which no standard therapy exists
- •ECOG (WHO) performance status 0-1
- •Life expectancy of at least 3 months
- •Age >=18 years
- •A negative pregnancy test (if female in reproductive years)
- •Acceptable liver and renal function
- •Acceptable hematologic status
- •Previous cancer therapy is allowed with the exclusion of experimental CDK2 inhibitors. Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy must be completed within one month prior to study entry
- •Use of effective contraceptive methods if men and women of child producing potential
- •Capability to swallow capsules intact
- •Grade <=1 retinopathy
排除标准
- •In the past 6 months: myocardial infarction, unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, pulmonary embolism, deep vein thrombosis
- •Known brain metastases
- •Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1
- •Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
- •Pregnant or breast feeding women
- •Unwillingness or inability to comply with procedures required in this protocol
- •Known infection with HIV, active hepatitis B or hepatitis C
- •Diabetes mellitus uncontrolled, or with clinical evidence of diabetic retinopathy, severe peripheral vascular disease or diabetic ulcers
- •Current enrollment in another clinical trial
- •Patients who have exhibited allergic reactions to a similar structural compound, biological agent, or formulation (lactose intolerance)
- •Previous history or current presence of neurological disorders, including epilepsy (although controlled by anticonvulsant therapy), Parkinson's disease, multiple sclerosis, stroke and cerebellar injury
- •Gastrointestinal disease (e.g. Crohn's disease, ulcerative colitis, or short gut syndrome) that would impact on drug absorption
- •Chronic/intensive use of antacid or H2 receptor antagonists
- •Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study or could compromise protocol objectives in the opinion of the investigator and/or the sponsor.
研究组 & 干预措施
Dose-escalation
Experimental
干预措施: PHA-848125AC (Drug)
结局指标
主要结局
Determination of Dose Limiting Toxicities and Maximum Tolerated Dose
时间窗: First cycle
次要结局
- Assessment of Adverse Events (based on CTCAE version 3.0)(All cycles)
- Evaluation of pharmacokinetics: plasma concentrations at different times after dosing and related assessment of conventional pharmacokinetic parameters(First 2 cycles)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
Oral Administration of STC-15 in Subjects with Advanced MalignanciesAdvanced CancerAdvanced Solid TumorCancerNCT05584111STORM Therapeutics LTD42
已完成
1 期
A Study to Assess the Effect of Hepatic Function on the Pharmacokinetics and Safety of ASP1941Liver DiseaseNCT01187186Astellas Pharma Inc16
进行中（未招募）
1 期
A phase I/II study of oral PHA-848125AC given daily for 14 consecutive days every 3 weeks in recurrent malignant gliomaPhase I Part: Recurrent Malignant GliomaPhase II Part: Recurrent Glioblastoma MultiformeMedDRA version: 9.1Level: LLTClassification code 10065443Term: Malignant gliomaMedDRA version: 9.1Level: LLTClassification code 10018337Term: Glioblastoma multiformeEUCTR2006-003193-10-FRerviano Medical Sciences S.r.l.70
撤回
1 期
Phase 1 Study of M9466 Combined With Carboplatin and Platinum-based Anticancer Therapy (DDRiver 521)Advanced Solid TumorsNCT06719973EMD Serono Research & Development Institute, Inc.54
已完成
1 期
Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic ImpairmentHepatic ImpairmentNCT03114540Pfizer29